Skip to content

Study · Randomized controlled trial · n = 179 · 2007

5 results

Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis.

Sellmeyer DE, Black DM, Palermo L, Greenspan S, Ensrud K, Bilezikian J, Rosen CJ

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA28 Feb 2007Cited by 21 (Europe PMC)

PMID17333451 (opens in a new tab)DOI10.1007/s00198-007-0336-x (opens in a new tab)PepBankPUB-17333451
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In osteoporotic women, the SD of cancellous spine BMD change was 32% with PTH versus 13% with alendronate (p < 0.0001).

    In plain wordsIn osteoporotic women, spine bone density responses varied more with PTH than with alendronate.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseCancellous spine BMD response variability
    Study

    n = 179

    Comparator
    Alendronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    SD of BMD change
    32%
    PTH
    SD of BMD change
    13%
    alendronate
    P value
    < 0.0001
    PTH vs alendronate

    Source sentences

    Summary
    The SD for change in cancellous spine BMD (by QCT) was 32% on PTH(1-84) compared to 13% on alendronate (p < 0.0001).
    1 context sentence
    Summary · context
    In the PaTH trial, among the 119 women randomized to parathyroid hormone PTH(1-84) and 60 to alendronate, we found much greater variation in BMD and markers in response to PTH(1-84) compared to alendronate.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In osteoporotic women, changes in bone formation markers varied significantly more with PTH than with alendronate.

    In plain wordsIn osteoporotic women, bone formation marker changes varied more with PTH than with alendronate.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseBone formation marker response variability
    Study

    n = 179

    Comparator
    Alendronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similarly, the SD of changes in markers of formation and resorption were significantly higher on PTH(1-84) than on ALN.
    1 context sentence
    Summary · context
    In the PaTH trial, among the 119 women randomized to parathyroid hormone PTH(1-84) and 60 to alendronate, we found much greater variation in BMD and markers in response to PTH(1-84) compared to alendronate.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In osteoporotic women, changes in bone resorption markers varied significantly more with PTH than with alendronate.

    In plain wordsIn osteoporotic women, bone resorption marker changes varied more with PTH than with alendronate.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseBone resorption marker response variability
    Study

    n = 179

    Comparator
    Alendronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similarly, the SD of changes in markers of formation and resorption were significantly higher on PTH(1-84) than on ALN.
    1 context sentence
    Summary · context
    In the PaTH trial, among the 119 women randomized to parathyroid hormone PTH(1-84) and 60 to alendronate, we found much greater variation in BMD and markers in response to PTH(1-84) compared to alendronate.
  4. 04HumanObservational studyOther

    In PTH-treated osteoporotic women, no baseline participant characteristic predicted increased bone density response.

    In plain wordsIn PTH-treated osteoporotic women, baseline characteristics did not predict greater bone density responses.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    No significant changeBaseline predictors of BMD response
    Study

    n = 119

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No baseline participant characteristics predicted increased bone density response to PTH(1-84) therapy.
    1 context sentence
    Summary · context
    In the PaTH trial, among the 119 women randomized to parathyroid hormone PTH(1-84) and 60 to alendronate, we found much greater variation in BMD and markers in response to PTH(1-84) compared to alendronate.
  5. 05HumanObservational studyOther

    In PTH-treated osteoporotic women, change in 1,25-OH(2)D explained 16% of variance in BMD response.

    In plain wordsIn PTH-treated osteoporotic women, vitamin D changes were linked to greater bone density gains.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseVitamin D change and BMD response association
    Study

    n = 119

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Variance explained
    16%
    BMD response

    Source sentences

    Summary
    However, change in 1,25-OH(2)D explained 16% of the variance in BMD response to PTH(1-84).
    2 context sentences
    Summary · context
    No baseline participant characteristic consistently predicted increased bone density response to PTH(1-84), although women with larger changes in 1,25 dihydroxyvitamin D during therapy had larger increases in BMD.
    Summary · context
    In the PaTH trial, among the 119 women randomized to parathyroid hormone PTH(1-84) and 60 to alendronate, we found much greater variation in BMD and markers in response to PTH(1-84) compared to alendronate.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.